Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Daniel S Chen"'
Autor:
Herbert Hurwitz, Daniel S. Chen
Publikováno v:
The Cancer Journal. 24:193-204
Cancer immunotherapy (CIT) has transformed cancer treatment. In particular, immunotherapies targeting the programmed death ligand 1 (PD-L1)/programmed death 1 pathway have demonstrated durable clinical benefit in some patients. However, CIT combinati
Autor:
Victor Cohen, Jamie E. Chaft, David S. Shames, Roel Funke, Zach Boyd, Peter Schmid, Vincent Leveque, Wei Zou, Simonetta Mocci, David R. Spigel, Hartmut Koeppen, Garret Hampton, Natasha Miley, Lukas C. Amler, Edward E. Kadel, Marcus Ballinger, Ira Mellman, Naiyer A. Rizvi, Geetha Shankar, Susan Flynn, Scott N. Gettinger, Dustin Smith, Fred R. Hirsch, Alan Sandler, Ignacio I. Wistuba, Marcin Kowanetz, Mark M. Kockx, Priti S. Hegde, Daniel S. Chen, Alexander I. Spira
Publikováno v:
Proceedings of the National Academy of Sciences of the United States of America
Significance Programmed death-ligand 1 (PD-L1) expression on tumor cells and tumor-infiltrating immune cells is regulated by distinct mechanisms and has nonredundant roles in regulating anticancer immunity, and PD-L1 on both cell types is important f
Autor:
Scott N. Gettinger, Ahmad Mokatrin, Daniel S. Chen, Priti S. Hegde, David F. McDermott, Yuanyuan Xiao, Donald P. Lawrence, Leora Horn, F. Stephen Hodi, John D. Powderly, J. A. Sosman, Omid Hamid, Ira Mellman, Jean-Charles Soria, Michael S. Gordon, Marcin Kowanetz, Hartmut Koeppen, Maya Leabman, Roy S. Herbst, Gregg Fine, Sandra Rost, Holbrook E Kohrt
Publikováno v:
Nature. 515:563-567
The development of human cancer is a multistep process characterized by the accumulation of genetic and epigenetic alterations that drive or reflect tumour progression. These changes distinguish cancer cells from their normal counterparts, allowing t
Publikováno v:
Clinical Cancer Research. 18:6580-6587
The aim of T-cell–based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patien
Autor:
Jennifer Jones, Daniel T. Chang, Daniel S. Chen, Joseph A. Mollick, Susan M. Hiniker, Susan M. Swetter, Susan J. Knox, Sunil Reddy
Publikováno v:
Translational Oncology. 5(6):404-407
BACKGROUND: Melanoma is a relatively immunogenic tumor, in which infiltration of melanoma cells by T lymphocytes is associated with a better clinical prognosis. We hypothesized that radiation-induced cell death may provide additional stimulation of a
Autor:
Daniel S. Chen, Ira Mellman
Publikováno v:
Nature. 541(7637)
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting
Autor:
Daniel S. Chen, J.M. Kim
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 27(8)
The emergence of programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1)-targeted therapy has demonstrated the importance of the PD-L1 : PD-1 interaction in inhibiting anticancer T-cell immunity in multiple human cancers, generating durable respo
Autor:
Fabien Gaire, Neeraj Sharma, Xian He, James W. Mier, Genevive Hernandez, David F. McDermott, Mario Sznol, Konstanty Korski, Jeffrey Wallin, Roel Funke, Galina Babitski, Daniel Waterkamp, Priti S. Hegde, Vincent Leveque, Daniel S. Chen, Hartmut Koeppen, James Ziai, Johanna C. Bendell, Marta Cañamero, Mitchell Denker, F. Stephen Hodi, Suzanne F. Jones
Publikováno v:
Nature Communications
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Nature Communications, Vol 7, Iss 1, Pp 1-8 (2016)
Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefit beyond a subset of patients. In preclinical models tumour-derived VEGF limits im
Autor:
Alessandra Castiglioni, Sanjeev Mariathasan, Ira Mellman, Edward E. Kadel, Kobe C. Yuen, Jillian L. Astarita, Suchit Jhunjhunwala, Rafael Cubas, Hartmut Koeppen, Yagai Yang, Shannon J. Turley, Yulei Wang, Richard Bourgon, Priti S. Hegde, Dorothee Nickles, Thomas Powles, Daniel S. Chen, Yasin Senbabaoglu
Publikováno v:
Cancer Research. 78:2979-2979
Checkpoint inhibitor blockade can result in robust and durable anti-tumor responses in various cancers, including metastatic urothelial cancer (mUC). However, these responses only occur in a subset of patients. Identifying determinants of response an
Autor:
Zachary Boyd, Rin Nakamura, Gregg Fine, Thomas Powles, Priti S. Hegde, Xiaodong Shen, Daniel P. Petrylak, Nicholas J. Vogelzang, Daniel S. Chen, Teiko Sumiyoshi, Christina Rabe, Mitchell Denker, Marcin Kowanetz, Siew-leng Melinda Teng, Qun J Wu, Yuanyuan Xiao, Yohann Loriot
Publikováno v:
Journal for Immunotherapy of Cancer
Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-d